HCP Live
Contagion LiveCGT LiveNeurology LiveHCP LiveOncology LiveContemporary PediatricsContemporary OBGYNEndocrinology NetworkPractical CardiologyRheumatology Netowrk

Endocrine Month in Review: November 2021

Editor's note: Clicking in the center of a slide will redirect you to that article or video.




Top Stories of November

  1. International Osteoporosis Foundation Issues Review of Links Between Bone Loss and Vascular Calcification
    The latest review from the International Osteoporosis Foundation is a 14-page document with more than 100 references outlining current data related to the pathophysiological links between vascular calcification and bone loss.
  2. Dapagliflozin Slows Rate of Kidney Function Decline, Regardless of Diabetes Status
    Data from a prespecified analysis of DAPA-CKD presented at Kidney Week 2021 provides insight into the effects of dapagliflozin use on the rate of kidney function decline based on the presence of type 2 diabetes from the trial.
  3. Diabetes Community Celebrates Build Back Better Act, Potential for $35 Insulin Caps
    Diana Isaacs, PharmD, discusses the Build Back Better Act, the potential impact of a monthly spending cap on insulin, and reflects on the progress that has been made in regard to insulin affordability during the 100-year anniversary of the discovery of insulin.
  4. CLICK Trial: Chlorthalidone Reduces BP in Chronic Kidney Disease and Uncontrolled Hypertension
    Data from the CLICK trial presented at Kidney Week 2021 demonstrates chlorthalidone reduced systolic blood pressure by 11 mmHg over a 12-week treatment period among a patient population with stage 4 CKD and uncontrolled hypertension.
  5. Patients with Diabetes Less Likely to Recognize, Report AFib Symptoms
    Data from the SWISS-AF study is providing clinicians with insight into the likelihood of patients to perceive symptoms of atrial fibrillation based on whether or not they had diabetes.
  6. Finerenone Could Reduce Progression to Dialysis in Type 2 Diabetes and CKD
    An analysis of secondary end points from FIGARO-DKD presented at Kidney Week 2021 provides further insight into the effects of finerenone on kidney outcomes, including a 36% reduction in need for dialysis.